To affinity and beyond: Harnessing the T Cell receptor for cancer immunotherapy

References

• Linnemann C, Mezzadra R, Schumacher TN. TCR repertoires of intratumoral T-cell subsets. Immunol Rev 2014; 257:72-82;PMID:24329790;http://dx.doi.org/10.1111/imr.12140
   PubMed Web of Science ®Google Scholar
• Muul LM, Spiess PJ, Director EP, Rosenberg SA. Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma. J Immunol (Baltimore, Md. : 1950) 1987; 138:989-995; PMID:3100623
   PubMed Web of Science ®Google Scholar
• Nikolich-Zugich J, Slifka MK, Messaoudi I. The many important facets of T-cell repertoire diversity. Nature reviews. Immunology 2004; 4:123-132; PMID:15040585; http://dx.doi.org/10.1038/nri1292
   PubMed Web of Science ®Google Scholar
• Chlewicki LK, Holler PD, Monti BC, Clutter MR, Kranz DM. High-affinity, peptide-specific T cell receptors can be generated by mutations in CDR1, CDR2 or CDR3. J Mole Biol 2005; 346:223-239; PMID:15663940; http://dx.doi.org/10.1016/j.jmb.2004.11.057
   PubMed Web of Science ®Google Scholar
• Reiser JB, Grégoire C, Darnault C, Mosser T, Guimezanes A, Schmitt-Verhulst AM, Fontecilla-Camps JC, Mazza G, Malissen B, Housset D. A T cell receptor CDR3beta loop undergoes conformational changes of unprecedented magnitude upon binding to a peptide/MHC class I complex. Immunity 2002; 16:345-354; PMID:11911820
   PubMed Web of Science ®Google Scholar
• Hurwitz AA, Cuss SM, Stagliano KE, Zhu Z. T Cell Avidity and Tumor Immunity: Problems and Solutions. Cancer Microenviron 2013; PMID:24357332; http://dx.doi.org/10.1007/s12307-013-0143-1
   PubMedGoogle Scholar
• Kalergis AM, Boucheron N, Doucey MA, Palmieri E, Goyarts EC, Vegh Z, Luescher IF, Nathenson SG. Efficient T cell activation requires an optimal dwell-time of interaction between the TCR and the pMHC complex. Nat Immunol 2001; 2:229-234; PMID:11224522; http://dx.doi.org/10.1038/85286
   PubMed Web of Science ®Google Scholar
• Stone JD, Chervin AS, Kranz DM. T-cell receptor binding affinities and kinetics: impact on T-cell activity and specificity. Immunology 2009; 126:165-176; PMID:19125887; http://dx.doi.org/10.1111/j.1365-2567.2008.03015.x
   PubMed Web of Science ®Google Scholar
• Rabinowitz JD, Beeson C, Wülfing C, Tate K, Allen PM, Davis MM, McConnell HM. Altered T cell receptor ligands trigger a subset of early T cell signals. Immunity 1996; 5:125-135; PMID:8769476
   PubMed Web of Science ®Google Scholar
• Kersh GJ, Kersh EN, Fremont DH, Allen PM. High- and low-potency ligands with similar affinities for the TCR: the importance of kinetics in TCR signaling. Immunity 1998; 9:817-826; PMID:9881972
   PubMed Web of Science ®Google Scholar
• Tian S, Maile R, Collins EJ, Frelinger JA. CD8+ T cell activation is governed by TCR-peptide/MHC affinity, not dissociation rate. J Immunol (Baltimore, Md. : 1950) 2007; 179:2952-2960; PMID:17709510
   PubMed Web of Science ®Google Scholar
• Chang JT, Palanivel VR, Kinjyo I, Schambach F, Intlekofer AM, Banerjee A, Longworth SA, Vinup KE, Mrass P, Oliaro J, et al. Asymmetric T lymphocyte division in the initiation of adaptive immune responses. Science (New York, N.Y.) 2007; 315:1687-1691; PMID:17332376; http://dx.doi.org/10.1126/science.1139393
   PubMed Web of Science ®Google Scholar
• King CG, Koehli S, Hausmann B, Schmaler M, Zehn D, Palmer E. T cell affinity regulates asymmetric division, effector cell differentiation, and tissue pathology. Immunity 2012; 37:709-720; PMID:23084359; http://dx.doi.org/10.1016/j.immuni.2012.06.021
   PubMed Web of Science ®Google Scholar
• Tan YX, Manz BN, Freedman TS, Zhang C, Shokat KM, Weiss A. Inhibition of the kinase Csk in thymocytes reveals a requirement for actin remodeling in the initiation of full TCR signaling. Nat Immunol 2014; 15:186-194; PMID:24317039; http://dx.doi.org/10.1038/ni.2772
   PubMed Web of Science ®Google Scholar
• Oh-hora M. Calcium signaling in the development and function of T-lineage cells. Immunol Rev 2009; 231:210-224; PMID:19754899; http://dx.doi.org/10.1111/j.1600-065X.2009.00819.x
   PubMed Web of Science ®Google Scholar
• Weber KS, Miller MJ, Allen PM. Th17 cells exhibit a distinct calcium profile from Th1 and Th2 cells and have Th1-like motility and NF-AT nuclear localization. J Immunol (Baltimore, Md. : 1950) 2008; 180:1442-1450; PMID:18209039
   PubMed Web of Science ®Google Scholar
• Fracchia KM, Pai CY, Walsh CM. Modulation of T Cell Metabolism and Function through Calcium Signaling. Front Immunol 2013; 4:324; PMID:24133495; http://dx.doi.org/10.3389/fimmu.2013.00324
   PubMed Web of Science ®Google Scholar
• Jenkins MR, Stinchcombe JC, Au-Yeung BB, Asano Y, Ritter AT, Weiss A, Griffiths GM. Distinct structural and catalytic roles for Zap70 in formation of the immunological synapse in CTL. eLife 2014; 3:e01310; PMID:24596147; http://dx.doi.org/10.7554/eLife.01310
   PubMedGoogle Scholar
• Jenkins MR, Tsun A, Stinchcombe JC, Griffiths GM. The strength of T cell receptor signal controls the polarization of cytotoxic machinery to the immunological synapse. Immunity 2009; 31:621-631; PMID:19833087; http://dx.doi.org/10.1016/j.immuni.2009.08.024
   PubMed Web of Science ®Google Scholar
• Xing Y, Hogquist KA. T-cell tolerance: central and peripheral. Cold Spring Harb Perspect Biol 2012; 4; PMID:22661634; http://dx.doi.org/10.1101/cshperspect.a006957
   PubMed Web of Science ®Google Scholar
• Bautista JL, Lio CW, Lathrop SK, Forbush K, Liang Y, Luo J, Rudensky AY, Hsieh CS. Intraclonal competition limits the fate determination of regulatory T cells in the thymus. Nat Immunol 2009; 10:610-617; PMID:19430476; http://dx.doi.org/10.1038/ni.1739
   PubMed Web of Science ®Google Scholar
• Leung MW, Shen S, Lafaille JJ. TCR-dependent differentiation of thymic Foxp3+ cells is limited to small clonal sizes. J Exp Med 2009; 206:2121-2130; PMID:19737865; http://dx.doi.org/10.1084/jem.20091033
   PubMed Web of Science ®Google Scholar
• Brown JH, Jardetzky TS, Gorga JC, Stern LJ, Urban RG, Strominger JL, Wiley DC. Three-dimensional structure of the human class II histocompatibility antigen HLA-DR1. Nature 1993; 364:33-39; PMID:8316295; http://dx.doi.org/10.1038/364033a0
   PubMed Web of Science ®Google Scholar
• Scott CA, Peterson PA, Teyton L, Wilson IA. Crystal structures of two I-Ad-peptide complexes reveal that high affinity can be achieved without large anchor residues. Immunity 1998; 8:319-329; PMID:9529149
   PubMed Web of Science ®Google Scholar
• Sim BC, Zerva L, Greene MI, Gascoigne NR. Control of MHC restriction by TCR Valpha CDR1 and CDR2. Science (New York, N.Y.) 1996; 273:963-966; PMID:8688082
   PubMed Web of Science ®Google Scholar
• Alam SM, Travers PJ, Wung JL, Nasholds W, Redpath S, Jameson SC, Gascoigne NR. T-cell-receptor affinity and thymocyte positive selection. Nature 1996; 381:616-620; PMID:8637599; http://dx.doi.org/10.1038/381616a0
   PubMed Web of Science ®Google Scholar
• Williams CB, Engle DL, Kersh GJ, Michael White J, Allen PM. A kinetic threshold between negative and positive selection based on the longevity of the T cell receptor-ligand complex. J Exp Med 1999; 189:1531-1544; PMID:10330432
   PubMed Web of Science ®Google Scholar
• Goldrath AW, Bevan MJ. Selecting and maintaining a diverse T-cell repertoire. Nature 1999; 402:255-262; PMID:10580495; http://dx.doi.org/10.1038/46218
   PubMed Web of Science ®Google Scholar
• Derbinski J, Schulte A, Kyewski B, Klein L. Promiscuous gene expression in medullary thymic epithelial cells mirrors the peripheral self. Nat Immunol 2001; 2:1032-1039; PMID:11600886; http://dx.doi.org/10.1038/ni723
   PubMed Web of Science ®Google Scholar
• Gotter J, Brors B, Hergenhahn M, Kyewski B. Medullary epithelial cells of the human thymus express a highly diverse selection of tissue-specific genes colocalized in chromosomal clusters. J Exp Med 2004; 199:155-166; PMID:14734521; http://dx.doi.org/10.1084/jem.20031677
   PubMed Web of Science ®Google Scholar
• Laan M, Peterson P. The Many Faces of Aire in Central Tolerance. Front Immunol 2013; 4:326; PMID:24130560; http://dx.doi.org/10.3389/fimmu.2013.00326
   PubMed Web of Science ®Google Scholar
• Gavanescu I, Benoist C, Mathis D. B cells are required for Aire-deficient mice to develop multi-organ autoinflammation: A therapeutic approach for APECED patients. Proc Natl Acad Sci U S A 2008; 105:13009-13014; PMID:18755889; http://dx.doi.org/10.1073/pnas.0806874105
   PubMed Web of Science ®Google Scholar
• Palmer E, Naeher D. Affinity threshold for thymic selection through a T-cell receptor-co-receptor zipper. Nature reviews. Immunology 2009; 9:207-213; PMID:19151748; http://dx.doi.org/10.1038/nri2469
   PubMed Web of Science ®Google Scholar
• McNeil LK, Starr TK, Hogquist KA. A requirement for sustained ERK signaling during thymocyte positive selection in vivo. Proc Natl Acad Sci U S A 2005; 102:13574-13579; PMID:16174747; http://dx.doi.org/10.1073/pnas.0505110102
   PubMed Web of Science ®Google Scholar
• Fu G, Casas J, Rigaud S, Rybakin V, Lambolez F, Brzostek J, Hoerter JA, Paster W, Acuto O, Cheroutre H, et al. Themis sets the signal threshold for positive and negative selection in T-cell development. Nature 2013; 504:441-445; PMID:24226767; http://dx.doi.org/10.1038/nature12718
   PubMed Web of Science ®Google Scholar
• Rudensky AY, Gavin M, Zheng Y. FOXP3 and NFAT: partners in tolerance. Cell 2006; 126:253-256; PMID:16873058; http://dx.doi.org/10.1016/j.cell.2006.07.005
   PubMed Web of Science ®Google Scholar
• Itoh M, Takahashi T, Sakaguchi N, Kuniyasu Y, Shimizu J, Otsuka F, Sakaguchi S. Thymus and autoimmunity: production of CD25+CD4+ naturally anergic and suppressive T cells as a key function of the thymus in maintaining immunologic self-tolerance. J Immunol (Baltimore, Md. : 1950) 1999; 162:5317-5326; PMID:10228007
   PubMed Web of Science ®Google Scholar
• Jordan MS, Boesteanu A, Reed AJ, Petrone AL, Holenbeck AE, Lerman MA, Naji A, Caton AJ. Thymic selection of CD4+CD25+ regulatory T cells induced by an agonist self-peptide. Nat Immunol 2001; 2:301-306; PMID:11276200; http://dx.doi.org/10.1038/86302
   PubMed Web of Science ®Google Scholar
• Moran AE, Holzapfel KL, Xing Y, Cunningham NR, Maltzman JS, Punt J, Hogquist KA. T cell receptor signal strength in Treg and iNKT cell development demonstrated by a novel fluorescent reporter mouse. J Exp Med 2011; 208:1279-1289; PMID:21606508; http://dx.doi.org/10.1084/jem.20110308
   PubMed Web of Science ®Google Scholar
• Sakaguchi S. Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 2005; 6:345-352; PMID:15785760; http://dx.doi.org/10.1038/ni1178
   PubMed Web of Science ®Google Scholar
• Gounaris E, Blatner NR, Dennis K, Magnusson F, Gurish MF, Strom TB, Beckhove P, Gounari F, Khazaie K. T-regulatory cells shift from a protective anti-inflammatory to a cancer-promoting proinflammatory phenotype in polyposis. Cancer Res 2009; 69:5490-5497; PMID:19570783; http://dx.doi.org/10.1158/0008-5472.can-09-0304
   PubMed Web of Science ®Google Scholar
• Kryczek I, Wei S, Zou L, Zhu G, Mottram P, Xu H, Chen L, Zou W. Cutting edge: induction of B7-H4 on APCs through IL-10: novel suppressive mode for regulatory T cells. J Immunol (Baltimore, Md. : 1950) 2006; 177:40-44; PMID:16785496
   PubMed Web of Science ®Google Scholar
• Ermann J, Szanya V, Ford GS, Paragas V, Fathman CG, Lejon K. CD4(+)CD25(+) T cells facilitate the induction of T cell anergy. J Immunol (Baltimore, Md. : 1950) 2001; 167:4271-4275; PMID:11591749
   PubMed Web of Science ®Google Scholar
• Oberle N, Eberhardt N, Falk CS, Krammer PH, Suri-Payer E. Rapid suppression of cytokine transcription in human CD4+CD25 T cells by CD4+Foxp3+ regulatory T cells: independence of IL-2 consumption, TGF-beta, and various inhibitors of TCR signaling. J Immunol (Baltimore, Md. : 1950) 2007; 179:3578-3587; PMID:17785792
   PubMed Web of Science ®Google Scholar
• Schmidt A, Oberle N, Weiss EM, Vobis D, Frischbutter S, Baumgrass R, Falk CS, Haag M, Brügger B, Lin H, et al. Human regulatory T cells rapidly suppress T cell receptor-induced Ca(2+), NF-kappaB, and NFAT signaling in conventional T cells. Sci Signal 2011; 4:ra90; PMID:22375050; http://dx.doi.org/10.1126/scisignal.2002179
   PubMed Web of Science ®Google Scholar
• Schmidt A, Oberle N, Krammer PH. Molecular mechanisms of treg-mediated T cell suppression. Front Immunol 2012; 3:51; PMID:22566933; http://dx.doi.org/10.3389/fimmu.2012.00051
   PubMed Web of Science ®Google Scholar
• Oderup C, Cederbom L, Makowska A, Cilio CM, Ivars F. Cytotoxic T lymphocyte antigen-4-dependent down-modulation of costimulatory molecules on dendritic cells in CD4+ CD25+ regulatory T-cell-mediated suppression. Immunology 2006; 118:240-249; PMID:16771859; http://dx.doi.org/10.1111/j.1365-2567.2006.02362.x
   PubMed Web of Science ®Google Scholar
• Yan Z, Garg SK, Kipnis J, Banerjee R. Extracellular redox modulation by regulatory T cells. Nat Chem Biol 2009; 5:721-723; PMID:19718041; http://dx.doi.org/10.1038/nchembio.212
   PubMed Web of Science ®Google Scholar
• Yan Z, Garg SK, Banerjee R. Regulatory T cells interfere with glutathione metabolism in dendritic cells and T cells. J Biol Chem 2010; 285:41525-41532; PMID:21037289; http://dx.doi.org/10.1074/jbc.M110.189944
   PubMed Web of Science ®Google Scholar
• Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 1995; 3:541-547; PMID:7584144
   PubMed Web of Science ®Google Scholar
• Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T, Miyara M, Fehervari Z, Nomura T, Sakaguchi S. CTLA-4 control over Foxp3+ regulatory T cell function. Science (New York, N.Y.) 2008; 322:271-275; PMID:18845758; http://dx.doi.org/10.1126/science.1160062
   PubMed Web of Science ®Google Scholar
• Della Vittoria Scarpati G, Fusciello C, Perri F, Sabbatino F, Ferrone S, Carlomagno C, Pepe S. Ipilimumab in the treatment of metastatic melanoma: management of adverse events. OncoTargets Ther 2014; 7:203-209; PMID:24570590; http://dx.doi.org/10.2147/ott.s57335
   PubMed Web of Science ®Google Scholar
• Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nature reviews. Cancer 2012; 12:252-264; PMID:22437870; http://dx.doi.org/10.1038/nrc3239
   PubMed Web of Science ®Google Scholar
• Nishimura H, Nose M, Hiai H, Minato N, Honjo T. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 1999; 11:141-151; PMID:10485649
   PubMed Web of Science ®Google Scholar
• Francisco LM, Salinas VH, Brown KE, Vanguri VK, Freeman GJ, Kuchroo VK, Sharpe AH. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med 2009; 206:3015-3029; PMID:20008522; http://dx.doi.org/10.1084/jem.20090847
   PubMed Web of Science ®Google Scholar
• Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, Sharpe AH, Freeman GJ, Ahmed R. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 2006; 439:682-687; PMID:16382236; http://dx.doi.org/10.1038/nature04444
   PubMed Web of Science ®Google Scholar
• Gros A, Robbins PF, Yao X, Li YF, Turcotte S, Tran E, Wunderlich JR, Mixon A, Farid S, Dudley ME, et al. PD-1 identifies the patient-specific CD8(+) tumor-reactive repertoire infiltrating human tumors. J Clin Invest 2014; 124:2246-2259; PMID:24667641; http://dx.doi.org/10.1172/jci73639
   PubMed Web of Science ®Google Scholar
• Yee C. The use of endogenous T cells for adoptive transfer. Immunol Rev 2014; 257:250-263; PMID:24329802; http://dx.doi.org/10.1111/imr.12134
   PubMed Web of Science ®Google Scholar
• Pittet MJ, Valmori D, Dunbar PR, Speiser DE, Liénard D, Lejeune F, Fleischhauer K, Cerundolo V, Cerottini JC, Romero P. High frequencies of naive Melan-A/MART-1-specific CD8(+) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals. J Exp Med 1999; 190:705-715; PMID:10477554
   PubMed Web of Science ®Google Scholar
• Lee PP, Yee C, Savage PA, Fong L, Brockstedt D, Weber JS, Johnson D, Swetter S, Thompson J, Greenberg PD, et al. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med 1999; 5:677-685; PMID:10371507; http://dx.doi.org/10.1038/9525
   PubMed Web of Science ®Google Scholar
• Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Sakaguchi K, Appella E, Yannelli JR, Adema GJ, Miki T, Rosenberg SA. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci U S A 1994; 91:6458-6462; PMID:8022805
   PubMed Web of Science ®Google Scholar
• Danke NA, Koelle DM, Yee C, Beheray S, Kwok WW. Autoreactive T cells in healthy individuals. J Immunol (Baltimore, Md. : 1950) 2004; 172:5967-5972; PMID:15128778
   PubMed Web of Science ®Google Scholar
• Bioley G, Jandus C, Tuyaerts S, Rimoldi D, Kwok WW, Speiser DE, Tiercy JM, Thielemans K, Cerottini JC, Romero P. Melan-A/MART-1-specific CD4 T cells in melanoma patients: identification of new epitopes and ex vivo visualization of specific T cells by MHC class II tetramers. J Immunol (Baltimore, Md. : 1950) 2006; 177:6769-6779; PMID:17082590
   PubMed Web of Science ®Google Scholar
• Jotereau F, Gervois N, Labarriere N. Adoptive transfer with high-affinity TCR to treat human solid tumors: how to improve the feasibility? Targeted Oncol 2012; 7:3-14; PMID:22350487; http://dx.doi.org/10.1007/s11523-012-0207-z
   PubMed Web of Science ®Google Scholar
• Goff SL, Smith FO, Klapper JA, Sherry R, Wunderlich JR, Steinberg SM, White D, Rosenberg SA, Dudley ME, Yang JC. Tumor infiltrating lymphocyte therapy for metastatic melanoma: analysis of tumors resected for TIL. J Immunother (Hagerstown, Md. : 1997) 2010; 33:840-847; PMID:20842052; http://dx.doi.org/10.1097/CJI.0b013e3181f05b91
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Spiess P, Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science (New York, N.Y.) 1986; 233:1318-1321; PMID:3489291
   PubMed Web of Science ®Google Scholar
• Dudley ME, Gross CA, Langhan MM, Garcia MR, Sherry RM, Yang JC, Phan GQ, Kammula US, Hughes MS, Citrin DE, et al. CD8+ enriched “young” tumor infiltrating lymphocytes can mediate regression of metastatic melanoma. Clin Cancer Res 2010; 16:6122-6131; PMID:20668005; http://dx.doi.org/10.1158/1078-0432.ccr-10-1297
   PubMed Web of Science ®Google Scholar
• Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry R, Restifo NP, Hubicki AM, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science (New York, N.Y.) 2002; 298:850-854; PMID:12242449; http://dx.doi.org/10.1126/science.1076514
   PubMed Web of Science ®Google Scholar
• Uchi H, Stan R, Turk MJ, Engelhorn ME, Rizzuto GA, Goldberg SM, Wolchok JD, Houghton AN. Unraveling the complex relationship between cancer immunity and autoimmunity: lessons from melanoma and vitiligo. Adv Immunol 2006; 90:215-241; PMID:16730265; http://dx.doi.org/10.1016/s0065-2776(06)90006-6
   PubMed Web of Science ®Google Scholar
• Yee C, Thompson JA, Roche P, Byrd DR, Lee PP, Piepkorn M, Kenyon K, Davis MM, Riddell SR, Greenberg PD. Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of t cell-mediated vitiligo. J Exp Med 2000; 192:1637-1644; PMID:11104805
   PubMed Web of Science ®Google Scholar
• Kyewski B, Klein L. A central role for central tolerance. Ann Rev Immunol 2006; 24:571-606; PMID:16551260; http://dx.doi.org/10.1146/annurev.immunol.23.021704.115601
   PubMed Web of Science ®Google Scholar
• Enouz S, Carrie L, Merkler D, Bevan MJ, Zehn D. Autoreactive T cells bypass negative selection and respond to self-antigen stimulation during infection. J Exp Med 2012; 209:1769-1779; PMID:22987800; http://dx.doi.org/10.1084/jem.20120905
   PubMed Web of Science ®Google Scholar
• Zhong S, Malecek K, Johnson LA, Yu Z, Vega-Saenz de Miera E, Darvishian F, McGary K, Huang K, Boyer J, Corse E, et al. T-cell receptor affinity and avidity defines antitumor response and autoimmunity in T-cell immunotherapy. Proc Natl Acad Sci U S A 2013; 110:6973-6978; PMID:23576742; http://dx.doi.org/10.1073/pnas.1221609110
   PubMed Web of Science ®Google Scholar
• Zehn D, Lee SY, Bevan MJ. Complete but curtailed T-cell response to very low-affinity antigen. Nature 2009; 458:211-214; PMID:19182777; http://dx.doi.org/10.1038/nature07657
   PubMed Web of Science ®Google Scholar
• Turner MJ, Jellison ER, Lingenheld EG, Puddington L, Lefrancois L. Avidity maturation of memory CD8 T cells is limited by self-antigen expression. J Exp Med 2008; 205:1859-1868; PMID:18625745; http://dx.doi.org/10.1084/jem.20072390
   PubMed Web of Science ®Google Scholar
• Irving M, Zoete V, Hebeisen M, Schmid D, Baumgartner P, Guillaume P, Romero P, Speiser D, Luescher I, Rufer N, et al. Interplay between T cell receptor binding kinetics and the level of cognate peptide presented by major histocompatibility complexes governs CD8+ T cell responsiveness. J Biol Chem 2012; 287:23068-23078; PMID:22549784; http://dx.doi.org/10.1074/jbc.M112.357673
   PubMed Web of Science ®Google Scholar
• Dougan SK, Dougan M, Kim J, Turner JA, Ogata S, Cho HI, Jaenisch R, Celis E, Ploegh HL. Transnuclear TRP1-specific CD8 T cells with high or low affinity TCRs show equivalent anti-tumor activity. Cancer Immunol Res 2013; 1:99-111; PMID:24459675; http://dx.doi.org/10.1158/2326-6066.cir-13-0047
   PubMed Web of Science ®Google Scholar
• Hebeisen M, Oberle SG, Presotto D, Speiser DE, Zehn D, Rufer N. Molecular insights for optimizing T cell receptor specificity against cancer. Front Immunol 2013; 4:154; PMID:23801991; http://dx.doi.org/10.3389/fimmu.2013.00154
   PubMed Web of Science ®Google Scholar
• Parkhurst MR, Yang JC, Langan RC, Dudley ME, Nathan DA, Feldman SA, Davis JL, Morgan RA, Merino MJ, Sherry RM, et al. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther 2011; 19:620-626; PMID:21157437; http://dx.doi.org/10.1038/mt.2010.272
   PubMed Web of Science ®Google Scholar
• Gill S, Kalos M. T cell-based gene therapy of cancer. Transl Res 2013; 161:365-379; PMID:23246626; http://dx.doi.org/10.1016/j.trsl.2012.11.002
   PubMed Web of Science ®Google Scholar
• Morgan RA, Dudley ME, Yu YY, Zheng Z, Robbins PF, Theoret MR, Wunderlich JR, Hughes MS, Restifo NP, Rosenberg SA. High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens. J Immunol (Baltimore, Md. : 1950) 2003; 171:3287-3295; PMID:12960359
   PubMed Web of Science ®Google Scholar
• Hofmann O, Caballero OL, Stevenson BJ, Chen YT, Cohen T, Chua R, Maher CA, Panji S, Schaefer U, Kruger A, et al. Genome-wide analysis of cancer/testis gene expression. Proc Natl Acad Sci U S A 2008; 105:20422-20427; PMID:19088187; http://dx.doi.org/10.1073/pnas.0810777105
   PubMed Web of Science ®Google Scholar
• Schuler-Thurner B, Schultz ES, Berger TG, Weinlich G, Ebner S, Woerl P, Bender A, Feuerstein B, Fritsch PO, Romani N, et al. Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells. J Exp Med 2002; 195:1279-1288; PMID:12021308
   PubMed Web of Science ®Google Scholar
• Kunert A, Straetemans T, Govers C, Lamers C, Mathijssen R, Sleijfer S, Debets R. TCR-Engineered T Cells Meet New Challenges to Treat Solid Tumors: Choice of Antigen, T Cell Fitness, and Sensitization of Tumor Milieu. Front Immunol 2013; 4:363; PMID:24265631; http://dx.doi.org/10.3389/fimmu.2013.00363
   PubMed Web of Science ®Google Scholar
• Morgan RA, Chinnasamy N, Abate-Daga D, Gros A, Robbins PF, Zheng Z, Dudley ME, Feldman SA, Yang JC, Sherry RM, et al. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother (Hagerstown, Md. : 1997) 2013; 36:133-151; PMID:23377668; http://dx.doi.org/10.1097/CJI.0b013e3182829903
   PubMed Web of Science ®Google Scholar
• Linette GP, Stadtmauer EA, Maus MV, Rapoport AP, Levine BL, Emery L, Litzky L, Bagg A, Carreno BM, Cimino PJ, et al. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood 2013; 122:863-871; PMID:23770775; http://dx.doi.org/10.1182/blood-2013-03-490565
   PubMed Web of Science ®Google Scholar
• Robbins PF, Lu YC, El-Gamil M, Li YF, Gross C, Gartner J, Lin JC, Teer JK, Cliften P, Tycksen E, et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nature medicine 2013; 19:747-752; PMID:23644516; http://dx.doi.org/10.1038/nm.3161
   PubMed Web of Science ®Google Scholar
• Tran E, Turcotte S, Gros A, Robbins PF, Lu YC, Dudley ME, Wunderlich JR, Somerville RP, Hogan K, Hinrichs CS, et al. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science (New York, N.Y.) 2014; 344:641-645; PMID:24812403; http://dx.doi.org/10.1126/science.1251102
   PubMed Web of Science ®Google Scholar
• Rosenberg SA. Finding suitable targets is the major obstacle to cancer gene therapy. Cancer Gene Ther 2014; 21:45-47; PMID:24535159; http://dx.doi.org/10.1038/cgt.2014.3
   PubMed Web of Science ®Google Scholar
• van den Berg HA, Wooldridge L, Laugel B, Sewell AK. Coreceptor CD8-driven modulation of T cell antigen receptor specificity. J Theor Biol 2007; 249:395-408; PMID:17869274; http://dx.doi.org/10.1016/j.jtbi.2007.08.002
   PubMed Web of Science ®Google Scholar
• Laugel B, van den Berg HA, Gostick E, Cole DK, Wooldridge L, Boulter J, Milicic A, Price DA, Sewell AK. Different T cell receptor affinity thresholds and CD8 coreceptor dependence govern cytotoxic T lymphocyte activation and tetramer binding properties. J Biol Chem 2007; 282:23799-23810; PMID:17540778; http://dx.doi.org/10.1074/jbc.M700976200
   PubMed Web of Science ®Google Scholar
• Gakamsky DM, Luescher IF, Pramanik A, Kopito RB, Lemonnier F, Vogel H, Rigler R, Pecht I. CD8 kinetically promotes ligand binding to the T-cell antigen receptor. Biophys J 2005; 89:2121-2133; PMID:15980174; http://dx.doi.org/10.1529/biophysj.105.061671
   PubMed Web of Science ®Google Scholar
• Wang A, Chandran S, Shah SA, Chiu Y, Paria BC, Aghamolla T, Alvarez-Downing MM, Lee CC, Singh S, Li T, et al. The stoichiometric production of IL-2 and IFN-gamma mRNA defines memory T cells that can self-renew after adoptive transfer in humans. Sci Transl Med 2012; 4:149ra120; PMID:22932225; http://dx.doi.org/10.1126/scitranslmed.3004306
   PubMed Web of Science ®Google Scholar
• Janicki CN, Jenkinson SR, Williams NA, Morgan DJ. Loss of CTL function among high-avidity tumor-specific CD8+ T cells following tumor infiltration. Cancer Res 2008; 68:2993-3000; PMID:18413769; http://dx.doi.org/10.1158/0008-5472.can-07-5008
   PubMed Web of Science ®Google Scholar
• Zhu Z, Singh V, Watkins SK, Bronte V, Shoe JL, Feigenbaum L, Hurwitz AA. High-avidity T cells are preferentially tolerized in the tumor microenvironment. Cancer Res 2013; 73:595-604; PMID:23204239; http://dx.doi.org/10.1158/0008-5472.can-12-1123
   PubMed Web of Science ®Google Scholar
• Shafer-Weaver KA, Anderson MJ, Stagliano K, Malyguine A, Greenberg NM, Hurwitz AA. Cutting Edge: Tumor-specific CD8+ T cells infiltrating prostatic tumors are induced to become suppressor cells. J Immunol (Baltimore, Md. : 1950) 2009; 183:4848-4852; PMID:19801511; http://dx.doi.org/10.4049/jimmunol.0900848
   PubMed Web of Science ®Google Scholar
• Ott PA, Hodi FS, Robert C. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. Clin Cancer Res 2013; 19:5300-5309; PMID:24089443; http://dx.doi.org/10.1158/1078-0432.ccr-13-0143
   PubMed Web of Science ®Google Scholar
• Finney HM, Akbar AN, Lawson AD. Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR zeta chain. J Immunol (Baltimore, Md. : 1950) 2004; 172:104-113; PMID:14688315
   PubMed Web of Science ®Google Scholar